Clinical trials: Supratentorial Brain Tumor
Pituitary Adenoma 1, Acth-Secreting
Pituitary Adenoma and Serum Lipid
Pituitary adenomas are usually benign monoclonal neoplasms caused by a mixture of pituicyte alterations together with a changed endocrine and paracrine regulatory milieu.
- Trial name
- NCT04021212
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Shandong Provincial Hospital
CerebroSpinal Fluid (CSF) Leak
NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery
Postoperative cerebrospinal fluid (CSF) leak is a significant complication of endoscopic endonasal approaches (EEA) to the skull base.
- Trial name
- NoSeal (NCT07216157)
- Testing
- Standard multilayer closure without sealant, Fibrin sealant application, Synthetic polyethylene glycol-based sealant
- Where
- Poland
- Volunteers
- 225 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Acromegaly Due to Pituitary Adenoma
Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
In this study, the investigators hypothesize that upfront gamma knife radiosurgery with drug therapy is superior in the treatment of growth hormone-secreting pituitary tumors after primary surgical treatment compared with the…
- Trial name
- MERGE (NCT03439709)
- Testing
- Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Samsung Medical Center
Pituitary Adenoma
Long-term Follow up for Retinal Vascular Changes After Endoscopic Endonasal Pituitary Surgery.
This study investigates the retinal vascular features, using optical coherence tomography angiography, in patients during one year's follow up after the endoscopic endonasal surgery to remove an intra-suprasellar pituitary…
- Trial name
- NCT04546386
- Testing
- Endoscopic endonasal pituitary surgery
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Federico II University
Acromegaly
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first…
- Trial name
- NCT02354508
- Testing
- Pasireotide LAR
- Where
- 50 sites in Argentina, Belgium and 13 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Brain and Central Nervous System Tumors
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy with peripheral stem cell or bone marrow transplant may allow the doctor to give…
- Trial name
- NCT00008008
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Postoperative Pain, Analgesia
Perioperative Multimodal Analgesia for Supratentorial Craniotomy
This randomized clinical trial aims to evaluate the effectiveness of scalp nerve blocks and dexmedetomidine in reducing opioid use and preventing postoperative delirium in patients undergoing supratentorial brain tumor surgery.
- Conditions
- Postoperative Pain, Analgesia, Supratentorial Brain Tumor
- Trial name
- NCT07441421
- Testing
- Dexmedetomidine, Scalp-Nerve Block
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Tiantan Hospital
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00107458
- Testing
- valproic acid
- Where
- 17 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group
Meningioma, Pituitary Disease
The Impact of Endoscopic Endonasal Skull Base Surgery on Olfaction
In this study, the research team will investigate the incidence and etiology of olfactory dysfunction following endoscopic endonasal skull base surgery, by combining clinical assessments with histomolecular analysis.
- Conditions
- Meningioma, Pituitary Disease, Pituitary Adenoma, Craniopharyngioma
- Trial name
- Endo-Olfact (NCT06874426)
- Testing
- Endoscopic endonasal skull base surgery
- Where
- 3 sites in Belgium, Germany and 1 more
- Volunteers
- 154 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pituitary Tumor
Postoperative Cognitive Dysfunction in Patients Undergoing Pituitary Removal Surgery
As postoperative cognitive dysfunction rates are high especially in elder patients, cognitive dysfunction is not diagnosed and treated effectively.
- Trial name
- NCT03719781
- Testing
- standardized minimental testing
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- Kocaeli University
Supratentorial Tumors
The Therapeutic Time Window of Mannitol During Craniotomy for Optimal Brain Relaxation in Patients With Supratentorial Tumours
Although mannitol is used for brain relaxation during neurosurgery and in the treatment of raised intracranial pressure; there is not a consensus on its safe, effective dose and the duration of its administration.
- Trial name
- NCT03444519
- Testing
- Mannitol
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Huashan Hospital
Cushing Disease, Pituitary Adenoma
FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease
The purpose of this research is to evaluate the performance [sensitivity, specificity, accuracy] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
- Trial name
- NCT07460232
- Testing
- Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Glioblastoma Multiforme, Anaplastic Astrocytoma
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
This Phase 1 study in patients with newly diagnosed malignant glioma is designed to determine the highest dose of IL13-PE38QQR that can be safely administered by Convection Enhanced Delivery (CED) to the area around the tumor…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma
- Trial name
- NCT00089427
- Testing
- IL13-PE38QQR, Surgery for placement, Radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- INSYS Therapeutics Inc
Supratentorial Brain Tumor
Effects of Two Different Goals of Fluid Management in Patients Undergoing Supratentorial Tumour Resection
Neurosurgical operations are characterised by major fluid shift, frequent use of diuretics, and prolonged operative time. The role of fluid therapy in these patients is very critical; hypovolemia might decrease cerebral…
- Trial name
- NCT05561894
- Testing
- pulse pressure variation index guided fluid therapy
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Assiut University
Adult Ependymoblastoma, Adult Giant Cell Glioblastoma
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
This pilot phase I/II trial studies the side effects and best dose of plerixafor after radiation therapy and temozolomide and to see how well it works in treating patients with newly diagnosed high grade glioma.
- Conditions
- Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT01977677
- Testing
- radiation therapy, temozolomide, plerixafor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Lawrence Recht
Brain and Central Nervous System Tumors, Neuroblastoma
Docetaxel in Treating Children With Recurrent Solid Tumors
Phase II trial to study the effectiveness of docetaxel in treating children with recurrent solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
- Trial name
- NCT00002825
- Testing
- filgrastim, docetaxel
- Where
- 36 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Supratentorial Brain Tumor
Influence of Intracranial Lesions on Bispectral Index
The purpose of this study is to assess whether BIS values at return of consciousness are different in patients with or without brain tumors.
- Trial name
- NCT01060631
- Testing
- BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- University Medical Center Groningen
Brain and Central Nervous System Tumors, Leukemia
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial
RATIONALE: Gathering information about why patients or their guardians agree or decline to participate in the optional pharmacokinetic portion of a phase I treatment study may help doctors plan clinical trials in the future.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00890435
- Testing
- questionnaire administration, psychosocial assessment and care
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Children's Oncology Group
Pituitary Diseases, Pituitary Neoplasms
Long Term Outcome Study in Patients With Pituitary Disorders
To determine the outcomes of patients with different pituitary disorders whether they are managed medically, surgically or expectantly.
- Trial name
- NCT03665064
- Volunteers
- 1,500 people
- Sponsor
- University of Alberta
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors…
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor
- Trial name
- NCT01088763
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 12 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)